Financial Review: StageZero Life Sciences (OTCMKTS:SZLSF) versus Oruka Therapeutics (NASDAQ:ORKA)

Oruka Therapeutics (NASDAQ:ORKA) and StageZero Life Sciences (OTCMKTS:SZLSF) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Oruka Therapeutics and StageZero Life Sciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	0	0	4	2	3.33
StageZero Life Sciences	0	0	0	0	N/A

Oruka Therapeutics presently has a consensus target price of $41.25, indicating a potential upside of 66.26%. Given Oruka Therapeutics’ higher probable upside, equities research analysts clearly believe Oruka Therapeutics is more favorable than StageZero Life Sciences.

Volatility & Risk

Oruka Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, StageZero Life Sciences has a beta of -0.18, suggesting that its stock price is 118% less volatile than the S&P 500.

Profitability

This table compares Oruka Therapeutics and StageZero Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-20.18%	-19.51%
StageZero Life Sciences	N/A	N/A	N/A

Valuation and Earnings

This table compares Oruka Therapeutics and StageZero Life Sciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$5.34 million	N/A	N/A
StageZero Life Sciences	$3.80 million	1.18	-$11.41 million	N/A	N/A

Oruka Therapeutics has higher earnings, but lower revenue than StageZero Life Sciences.

Summary

Oruka Therapeutics beats StageZero Life Sciences on 5 of the 8 factors compared between the two stocks.

About Oruka Therapeutics

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.

About StageZero Life Sciences

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.